Site hosted by Angelfire.com: Build your free website today!
Blog Tools
Edit your Blog
Build a Blog
RSS Feed
View Profile
« July 2016 »
S M T W T F S
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31
Entries by Topic
All topics  «
You are not logged in. Log in
All About Endocrinology
Monday, 4 July 2016
Understanding Diabetic Sensory and Motor Neuropathy

Diabetes is a metabolic disease. When left unmanaged, it can lead to several complications. Sensory and motor neuropathy are among the known complications of the disease. At least half of those with diabetes suffer from it. Aside from being the most common, sensory and motor neuropathy are also among the most unpleasant complications of diabetes.

The loss of nerve function among diabetics doesn’t just impede the motor abilities but can also lead to cardiac arrhythmias, foot ulcers, sprains, fractures, and even amputations. These greatly reduce a diabetic’s quality of life and in worst some cases, can be the cause of one’s death.

Sensorimotor Neuropathy

In sensory motor neuropathy, the senses and reflexes on the limbs are reduced. This usually begins on the lower extremities, particularly on the toes then gradually moving up along the leg. It is characterized by bouts of numbness, loss of sensation and prickling, and burning pain at night. Sometimes, the patient would complain of proprioception, a kind of feeling on which the person doesn’t have a clue on where his limb is.

This loss of sensation on the limbs makes it harder for a diabetic to notice that he has stepped into a foreign object. A lot of videos have shown diabetics stepping on a nail but barely noticing it until he saw his foot bleeding.

This is actually the worst complication of the disease as this causes delay in treatment. It can also  aggravate the person’s condition. A simple wound can end up in toe or foot amputation due to deep infection or ulcers.

Other complications of sensorimotor neuropathy include the following:

  • Charcot joint which is a result of numerous fractures on the ankle, foot, or knee

  • Toe contractures which may cause the hand or toe to look gaunt or without muscles

  • Reduced dorsiflexion

Managing Sensorimotor Neuropathy

Because sensorimotor neuropathy could sometimes be detected as early as the diabetes itself, your doctor should already be vigilant for signs of this condition and make plans to manage it. Failure to diagnose this early can lead to drastic consequences like amputation or death.

Most management plans for sensorimotor neuropathy can either fall into those that provide short-term relief or those that can be categorized as progressive therapies.

Short-term relief management plans aim to address bouts of pain or discomfort while progressive therapies aim to slow down the effect of the condition.

Apart from therapies, here are other ways to manage the complications of sensorimotor neuropathy:

  • Stabilize glycemia

  • Manage pain through medications

  • Take care of your feet

This and other complications of diabetes can be avoided if you learn to change some aspects of your lifestyle. Quitting unhealthy habits like smoking, drinking alcohol, and overeating can definitely reduce your risk of sensorimotor neuropathy and other diabetes-related complications.

Posted by endocrinology at 11:44 PM EDT
Post Comment | Permalink | Share This Post
Wednesday, 22 June 2016
Fighting advanced thyroid cancer with immunotherapy

 

According to the American Cancer   Society, the chance of being diagnosed with thyroid cancer has risen rapidly in the United States in recent years. This appears to be due to increased use of technology to detect thyroid nodules that may not otherwise been found previously. Most thyroid cancers can be treated successfully, but advanced cases can be difficult to treat, especially if they do not respond to radioactive iodine (RAI) therapy. New treatments called 'immunotherapies' are being explored. They target a certain protein that has the ability to shut down T cells -- a part of white blood cells that help the body fight infection and disease naturally. In blocking this activity, these new immunotherapy drugs help T cells get back to work in protecting the body.

Janice M. Mehnert, MD, director of the Phase I and Developmental Therapeutics Program at Rutgers Cancer Institute of New Jersey, is the lead author of research highlighting the immunotherapy drug pembrolizumab and its effect on advanced thyroid cancer. The work is being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting which begins tomorrow in Chicago. Dr. Mehnert, who is also a medical oncologist in the Melanoma and Soft Tissue Oncology Program at Rutgers Cancer Institute, shares more about the research:

Q: How was the study structured?

A: At the time our abstract was submitted, 22 patients with a diagnosis of advanced or metastatic papillary or follicular thyroid cancer who failed prior standard therapy were accrued from multiple international sites. Participants received 10 mg of pembrolizumab every two weeks for up to 24 months or until confirmed progression or unacceptable toxicity. Safety, tolerability and response were assessed every eight weeks for the first six months and every 12 weeks thereafter.

Q: What did you find?

A: At the time we reported our results, six of the 22 patients remained on treatment. Of those who completed therapy, two patients had a partial response for an overall response rate of 9.1 percent, and there was a stable disease rate of 54.5 percent. The six-month overall survival rate was 100 percent and the six month progression free survival rate was 58.7 percent. Updated results will be announced at the annual meeting. There were no treatment-related deaths or therapy discontinuations due to drug-related adverse effects. Overall, pembrolizumab shows promising antitumor activity in advanced cases of follicular or papillary thyroid cancer which progressed on standard treatment. The clinical benefit of pembrolizumab in advanced thyroid cancer will be further studied in a follow-up phase II clinical trial that is now ongoing to try to discover biomarkers which predict response to treatment with pembrolizumab.

Q: How are immunotherapy drugs changing the landscape of cancer treatment?

A: Although many patients treated do not respond, when immunotherapy does induce responses in patients with advanced cancers, these responses may be very long lasting in terms of disease control. As well, at least when used as single agents, these agents tend to confer side effects that patients find much more tolerable than those associated with chemotherapy. It's an exciting time in early phase drug development when we are observing these results in so many different types of cancer.

 


Posted by endocrinology at 7:36 PM EDT
Updated: Wednesday, 22 June 2016 7:38 PM EDT
Post Comment | Permalink | Share This Post

Newer | Latest | Older